# Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

> **NCT06869174** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhiguo Luo, MD, PhD** · enrollment: 50 (estimated)

## Conditions studied

- Cancer of Unknown Primary

## Interventions

- **DRUG:** Pucotenlimab combined with MRG002

## Key facts

- **NCT ID:** NCT06869174
- **Lead sponsor:** Zhiguo Luo, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-08
- **Primary completion:** 2027-03-08
- **Final completion:** 2028-08-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06869174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06869174, "Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06869174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*